Sorafenib

COMPOSITION:

Each film-coated tablet contains Sorafenib tosylate 274 mg equivalent to Sorafenib………………………200mg.

INDICATIONS

LuciSora is a kinase inhibitor indicated for the treatment of

• Unresectable hepatocellular carcinoma.

• Advanced renal cell carcinoma.

• Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

DOSAGE AND USE:

• 400 mg (2 tablets) orally twice daily without food.

• Treatment interruption and/or dose reduction may be needed to manage adverse reactions.

STORAGE:

In a dry place and store at 20℃ to 25℃.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNINGS:

Keep medicine out of reach of Children. Do not administer LuciSora during Pregnancy and Lactation.